AlphaValue Corporate Services
COVERAGE ABOUT US CONTACT FR
This research has been commissioned and paid for by the company and does therefore not constitute an inducement caught by the prohibition under MiFID II

Crossject

CR 		Bloomberg   ALCJ FP
Supergenerics  /  France  Web Site   |   Investors Relation
Things are getting going...hopefully in FY25
Target
Upside 279%
Price (€) 1.78
Target Price (€) 6.75
Market Cap (€M) 80.0
Perf. 1W: 1.20%
Perf. 1M: -12.1%
Perf. 3M: -6.43%
Perf Ytd: -18.4%
10 day relative perf. to stoxx600: 2.22%
20 day relative perf. to stoxx600: -12.2%
EPS change22/05/2020 16:38
Download

No major changes after the release of the FY19 report
Change in EPS2019 : € -0.49 vs -0.48ns
2020 : € -0.32 vs -0.34ns

No major changes to our forecasts. The only ones come from the integration of the detailed FY19 numbers which marginally impact our forecasts, with hardly any change to our target price.
Updates
.